Incyte’s latest therapy, INCA033989, is making waves in the rare blood cancer world. Early trial results show big improvements for myelofibrosis patients, especially those with CALR mutations—think smaller spleens, better anemia, and way fewer symptoms. Even people who didn’t respond to other treatments saw benefits. Bonus: it works solo or paired with ruxolitinib, and side effects seem chill. Could this be a game-changer for blood cancer? #Health #BodyHealth #CancerResearch